Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neurocomputational Mechanisms of Mood Improvement
NCT04276259Phase 4Completed
- Sponsor
- Marta Peciña
- Start
- Oct 2020
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of buprenorphine extended-release injection, naltrexone in major depressive disorder (MDD), sponsored by Marta Peciña. Started Oct 2020; status: completed.
02
Drugs
buprenorphine extended-release injectionnaltrexone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04276259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04276259.